Royalty Pharma Plc (RPRX)

Healthcare · Biotechnology
$56.44 -0.39% on the day Market cap $32.0B 52-week range $35.23 to $64.38 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Royalty Pharma Plc's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

C

Five factors scored 1 to 9 from RPRX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability7
Growth4
Financial health5

Key numbers

P/E (trailing)29.2x
P/E (forward)45.7x
Price / free cash flow12.8x
EV / EBITDA18.9x
Price / sales12.6x
Price / book3.55x
Revenue growth+16.5%
Operating margin59.6%
Net margin32.1%
Return on equity8.3%
Dividend yield1.6%
Debt / equity1.03x

Results from SEC filings

Fiscal years, from Royalty Pharma Plc's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$2.3B$2.2B$2.4B$2.3B$2.4B
Net income$620M$43M$1.1B$859M$771M
Free cash flow—————
EPS (diluted)$1.49$0.10$2.53$1.91$1.78
Operating margin62.5%13.7%63.4%57.1%65.6%

Where the revenue comes from

Revenue by products, fiscal 2025.

Income from financial royalty assets$2.3B95%
Other royalty income and revenues$117M5%

Superinvestors who own RPRX

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $241M0.08%Q2 2026
Murray Stahl
Horizon Kinetics LLC
Added $19M0.22%Q2 2026
Will Nasgovitz
Heartland Advisors
Trimmed $11M0.51%Q2 2026

Insider buying

Open-market purchases by Royalty Pharma Plc's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of RPRX in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when RPRX trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Royalty Pharma Plc insiders buying the stock?

No open-market insider purchases of RPRX in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Royalty Pharma Plc?

3 of the superinvestors Investingly tracks hold RPRX in their latest 13F, including Cliff Asness, Murray Stahl, Will Nasgovitz.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.